Tratamiento de la infección por el VIH

  1. Guerrero Sánchez, Francisca
  2. Arizcorreta Yarza, A.
  3. Gutiérrez Saborido, D.
  4. Ruiz Estévez, B.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2014

Título del ejemplar: Enfermedades infecciosas (I): infecciones víricas, infección por VIH

Serie: 11

Número: 49

Páginas: 2912-2919

Tipo: Artículo

DOI: 10.1016/S0304-5412(14)70714-0 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

El tratamiento antirretrovírico ha modificado la historia natural de la infección por VIH. El tratamiento consiguió inicialmente �salvar vidas� y posteriormente suprimir los efectos indeseables graves de los fármacos. La aparición en los últimos años de nuevos fármacos con mejor perfil de seguridad permiten no sólo tratar sino incluso prevenir. Las estrategias para facilitar la adherencia se convierten en la base para evitar la aparición de resistencias.

€ Ver financiación

Información de financiación

65 2010 1505 1509 32. Panel de Expertos de Gesida-SEIMC y Plan Nacional sobre el Sida. Recomendaciones de Gesida/Plan Nacional sobre el Sida para el tratamiento de la tuberculosis en adultos infectados por el virus de la inmunodeficiencia humana. [Actualizado enero de 2013). Disponible en: www.gesidaseimc.org/pcientifica/dcconsensos . 33. Grupo de expertos de la Secretaría del Plan Nacional sobre el Sida (SPNS), Grupo de Estudio del Sida (GESIDA), Sociedad Española de Ginecología y Obstetricia (SEGO) y Sociedad española de Infectología Pediátrica /SEIP). Guía práctica para el seguimiento de la infección por VIH en relación con la reproducción, embarazo, parto y profilaxis de la transmisión vertical del niño expuesto (2013). Disponible en: www.gesidaseimc.org/pcientifica/dcconsensos.aspapnv0=pcientifica&apnvA=dcconsensosyrc&appag=dcconsensos_txt.htm . 34. C.L. Thio S. Locarnini

Financiadores

Referencias bibliográficas

  • J.B. Dinoso, S.Y. Kim, A.M. Wiegand, S.E. Palmer, S.J. Gange, L. Cranmer Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy Proc Natl Acad Sci U S A, 106 (2009), pp. 9403-9408
  • T.W. Chun, L. Stuyver, S.B. Mizell, L.A. Ehler, J.A. Mican, M. Baseler Presence of an inducible HIV-1 latent reservoir during highly active antirretroviral therapy Proc Natl Acad Sci U S A, 94 (1997), pp. 13193-13197
  • T.W. Chun, L. Engel Derey, A.S. Fauci Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection Proc Natl Acad Sci U S A, 95 (1998), pp. 8869-8873
  • W.A. O’Brien, P.M. Hartigan, D. Martin, J. Esinhart, A. Hill, S. Benoit Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS N Engl J Med, 334 (1996), pp. 426-431
  • F. García, E. de Lazzari, M. Plana, P. Castro, G. Mestre, M. Nomdedeu Long-term CD4+ T-cell response to highly active antirretroviral therapy according to baseline CD4+ T-cell count J Acquir Immune Defic Syndr, 36 (2004), pp. 702-713
  • M.A. Thompson, J.A. Aberg, J.F. Hoy, A. Telenti, C. Benson, P. Cahn Antirretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel JAMA, 4 (2012), pp. 387-402
  • M.M. Kitahata, S.J. Gange, A.G. Abraham, B. Merriman, M.S. Saag, A.C. Justice, et al., NAACCORD Investigators Effect of early versus deferred antirretroviral therapy for HIV on survival N Engl J Med, 360 (2009), pp. 1815-1826
  • The Antirretroviral Therapy Cohort Collaboration Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies Lancet, 372 (2008), pp. 293-299
  • C. Lewden, G. Chene, P. Morlat, F. Raffi, M. Dupon, P. Dellamonica HIV infected adults with a CD4 cell count greater than 500 cells/mm3 on long term combination antiretroviral therapy reach same mortality rates as the general population J Acquir Immune Defic Syndr, 46 (2007), pp. 72-77
  • R. Tubiana, J. Le Chenadec, C. Rouzioux, L. Mandelbrot, K. Hamrene, C. Dollfus Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load < 500 copies/ml at delivery: a casecontrol study nested in the French perinatal cohort (EPF-ANRS CO1) Clin Infect Dis, 50 (2010), pp. 585-596
  • S. Attia, M. Egger, M. Muller, M. Zwahlen, N. Low Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis AIDS, 23 (2009;), pp. 1397-1404
  • K.N. Ly, J. Xing, R.M. Klevens, R.B. Jiles, J.W. Ward, S.D. Holmberg The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007 Ann Intern Med, 156 (2012), pp. 271-278
  • I.C. Marschner, A.C. Collier, R.W. Coombs, R.T. D’Aquila, V. DeGruttola, M.A. Fischl Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy J Infect Dis, 177 (1998), pp. 40-47
  • D.M. Moore, R.S. Hogg, B. Yip, K. Craib, E. Wood, J.S. Montaner CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL HIV Med, 7 (2006), pp. 383-388
  • F. Brañas, J. Berenguer, M. Sánchez Conde, J.C. López Bernaldo de Quiros, P. Miralles, J. Cosin The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy Am J Med, 121 (2008), pp. 820-824
  • K.A.G.S. Althoff A critical epidemiologic review of cardiovascular disease risk in HIV-infected adults: The importance of the HIV-uninfected comparison group, confounding, and competing risks HIV Medicine, 14 (2013), pp. 191-192
  • F.X. Lescure, L.H. Omland, F.N. Engsig, C. Roed, J. Gerstoft, G. Pialoux Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study Clin Infect Dis, 52 (2011), pp. 235-243
  • R.K. Heaton, D.B. Clifford, D.R. Franklin Jr., J.A. McCutchan, S.L. Letendre, S. Leblanc HIV associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study Neurology, 75 (2010), pp. 2087-2096
  • R.C. Kalayjian, N. Franceschini, S.K. Gupta, L.A. Szczech, E. Mupere, R.J. Bosch Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease AIDS, 22 (2008), pp. 481-487
  • S. Mallal, E. Phillips, G. Carosi, J.M. Molina, C. Workman, J. Tomazic HLA-B*5701 screening for hypersensitivity to abacavir N Engl J Med, 358 (2008), pp. 568-579
  • J.K. Rockstroh, E. DeJesus, J.L. Lennox, Y. Yazdanpanah, M.S. Saag, H. Wan STARTMRK Investigators Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1 infected patients: final 5 year results from STARTMRK J Acquir Immune Defic Syndr, 63 (2013), pp. 77-85
  • F. Raffi, A. Rachlis, H.J. Stellbrink, W.D. Hardy, C. Torti, C. Orkin Once daily dolutegravir versus raltegravir in antiretroviral naive adults with HIV-1 infection: 48 week results from the randomised, doubleblind, non inferiority SPRING-2 study Lancet, 381 (2013), pp. 735-743
  • J.A. Bartlett, M.J. Fath, R. DeMasi, A. Hermes, J. Quinn, E. Mondou An updated systematic overview of triple combination therapy in antiretroviral naive HIV infected adults AIDS, 20 (2006;), pp. 2051-2064
  • M. Airoldi, M. Zaccarelli, L. Bisi, T. Bini, A. Antinori, C. Mussini Onepill once a day HAART: a simplification strategy that improves adherence and quality of life of HIV infected subjects Patient Prefer Adherence, 4 (2010), pp. 115-125
  • J.M. Molina, J. Andrade Villanueva, J. Echevarria, P. Chetchotisakd, J. Corral, N. David Once daily atazanavir/ritonavir compared with twicedaily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral naive HIV-1 infected patients: 96 week efficacy and safety results of the CASTLE study J Acquir Immune Defic Syndr, 53 (2010), pp. 323-332
  • M. Nelson, P.M. Girard, R. DeMasi, L. Chen, E. Smets, V. Sekar Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment naive, HIV infected patients: 96 week ARTEMIS data J Antimicrob Chemother, 65 (2010), pp. 1505-1509
  • C.L. Thio, S. Locarnini Treatment of HIV/HBV coinfection: clinical and virologic issues AIDS Rev, 9 (2007), pp. 40-53
  • J.J. Parienti, D.R. Bangsberg, R. Verdon, E.M. Gardner Better adherence with once daily antiretroviral regimens: a meta analysis Clin Infect Dis, 48 (2009), pp. 484-488
  • E. Martínez, P.M. D’Albuquerque, J.M. Llibre, F. Gutiérrez, D. Podzamczer, A. Antela Changes of cardiovascular biomarkers in HIV-infected patients switching from ritonavir boosted protease inhibitors to raltegravir AIDS, 26 (2012), pp. 2315-2326
  • E. Martínez, M. Larrousse, J.M. Llibre, F. Gutiérrez, M. Saumoy, A. Antela Substitution of raltegravir for ritonavir boosted protease inhibitors in HIVinfected patients: the SPIRAL study AIDS, 24 (2010), pp. 1697-1707
  • S. Mathis, B. Khanlari, F. Pulido, M. Schechter, E. Negredo, M. Nelson Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta analysis PLoS One, 6 (2011), p. e22003
  • Fabbiani M, Colafigli M, Farina S, D’Avino A, Mondi A, Bianco C Treatment simplification to atazanavir/ritonavir plus lamivudine QD in patients on two NRTIs plus atazanavir/ritonavir with optimal virologic control: 96 weeks follow up of a pilot study (Atazanavir and Lamivudine Simplification Study, ATLAS) Program and abstracts of the 19nd International AIDS Conference. July 22-27, 2012; Washington DC, USA. Abstract TUPE097.
Fuente de los datos: Dialnet